Ocean Biomedical (OCEA) shares were up 88% premarket Wednesday after the company said that its co-founder, Jonathan Kurtis, and his research team have received additional funding from the National Institutes of Health to further their malaria vaccine research.
The company said that recent US Food and Drug Administration guidance on lipid-encapsulated vaccines could provide an expedited development pathway for their approach.
Ocean Biomedical said it could potentially begin human trials as early as Q4.